Clinical TrialMay 18, 2026, 04:07 PM
Mineralys to present Phase 3 lorundrostat data for hypertension in CKD
AI Summary
Mineralys Therapeutics announced that new data from its Phase 3 Launch-HTN trial for lorundrostat in patients with uncontrolled hypertension and chronic kidney disease (CKD) will be presented at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026). The oral presentation will highlight the efficacy and safety profile of lorundrostat, an aldosterone synthase inhibitor designed to reduce aldosterone levels. The company has completed six late-stage clinical trials, including the pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials, which demonstrated robust and clinically meaningful reductions in systolic blood pressure with a favorable safety profile.
Key Highlights
- New data from Phase 3 Launch-HTN trial for lorundrostat to be presented at ESH 2026.
- Presentation will highlight efficacy and safety profile of lorundrostat in hypertension and CKD.
- Lorundrostat is a highly selective aldosterone synthase inhibitor with 374-fold selectivity.
- Demonstrated 40-70% reduction in plasma aldosterone concentration in hypertensive participants.
- Completed six late-stage clinical trials, including two pivotal Phase 3 and Phase 2 trials.
- CKD affects over 10% of global population; hypertension causes >685,000 deaths in US in 2022.
Price Impact
More from MLYS